OXFORD, UNITED KINGDOM and PRINCETON, NJ--(Marketwire - March 28, 2011) - M5 Medical has signed a distribution agreement with Mirada Medical to sell Mirada's XD3 advanced imaging software for oncology assessment and follow-up. This broadens M5 Medical's offerings, which now include a full array of service packages, new and refurbished imaging hardware, and cutting-edge multi-modality software.
XD3 provides users with fusion of any combination of vendor neutral CT, PET, MR and SPECT images at a fraction of the cost of a hybrid system. M5 is excited about XD3's tri-modal fusion, which allows users to fuse an MR scan with a PET/CT scan. This unique capability enables users to assess tumors and soft tissue abnormalities that are better visualized with MR than with CT.
Additionally, Mirada's optimized CT-CT deformable registration aligns images taken across multiple timepoints. This enables patient follow-up and region tracking -- an important feature for assessing response to treatment or disease progression for cancer patients.
The XD3 software can be acquired as a software package, integrated with a powerful workstation or with any of the M5 Medical high quality refurbished systems (PET, CT, MRI, and SPECT).
About Mirada Medical
Mirada Medical is an internationally recognized brand in advanced medical imaging. The company develops high value clinical software applications, which are used across diagnostic radiology, nuclear medicine, radiation oncology, tumor board and elsewhere.
Mirada specializes in simplifying technically complex image quantification, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention.
Mirada was originally spun out of the University of Oxford. The company's technologies are, to this day, developed by a team of dedicated engineers and world-renowned scientists working out of Oxford, England.
Mirada's products have been designed to ease the deployment of these powerful technologies into any hospital or imaging center workflow. Mirada's applications can be delivered using thin client or cloud based architectures, or licensed on a floating or per workstation basis.
Most recently, Mirada has focused on the development of disease specific solutions for use across departments working with patients to fight cancer. In particular, Mirada's powerful image registration technologies have been tuned to the needs of radiation oncology, and quantification technologies have been redefined to optimize support for standard protocols such as RECIST and PERCIST. In addition, powerful imaging solutions have been introduced to support better collaborative working, in particular in the context of a rich web-based viewer for referring physicians and a robust solution for presentation of images at tumor board.
About M5 Medical
M5 Medical is a full-service partner to the medical imaging community. M5 provides service, sales, support, and consulting for both diagnostic and therapeutic imaging. Is serves the five major modalities of radiology (PET, NM, CT, MR, and US). Although M5 was created in September 2010, its engineers are known throughout the industry and have nearly a century of experience in diagnostic and therapeutic imaging service and support. For more information please visit www.m5medical.com
For more information, please contact:
Mirada Medical
enquiries@mirada-medical.com
Europe:
Hugh Bettesworth
CEO
tel: +44 (0) 1865 811172
US: Mary Beth Archibald
EVP, US Service and Operations
tel: +1 816 536 8385
